Tutorials › Adaptive Clinical Trial Design › Steering Committees and Strategic Oversight

Adaptive Platform Governance · Tutorial 708 of 799

Steering Committees and Strategic Oversight

Understand who may serve on a platform steering committee, what strategic oversight it provides, and how to recognize when its role is unclear or overextended.

Intermediate 9 min read

What You'll Learn

  • Explain how platform-wide strategy differs from operational management and arm-specific decisions.
  • Identify stakeholder groups that may need representation on a steering committee.
  • Describe how a committee can set scientific priorities and review the overall portfolio.
  • Distinguish committee advice from decisions formally delegated to it.
  • Recognize conflicts of interest, unclear authority, and other signs of weak oversight.
  • Apply these principles to hypothetical platform-governance situations.

Why a Platform Needs Strategic Oversight

An adaptive platform can study multiple interventions over time under a shared framework. Its direction therefore affects more than one arm: decisions about the platform’s mission, scientific emphasis, or use of shared capacity may have consequences across the portfolio. A steering committee provides a forum for considering those platform-wide consequences together rather than allowing each participating group to act only on its own priorities.

The committee’s value depends on its remit being clear. It should help set and review strategy, scientific priorities, and the health of the overall portfolio. It should not become a substitute for a sponsor’s accountability, take on decisions that belong to another delegated body, or blur the distinction between strategic direction and operational execution. The earlier material on decision rights and delegation maps, and on sponsor responsibilities in shared-control platforms, provides useful context for those boundaries.

Definition: A platform steering committee is a governance body charged with considering the platform’s overall direction and portfolio, and with making or recommending platform-level decisions within an explicitly defined remit. Its exact membership, voting arrangements, and authority depend on the platform’s governance agreements; there is no single universal committee structure.

The committee operates within the applicable protocol, agreements, and regulatory and institutional requirements. Its remit cannot override those requirements. Nor does forming a committee, by itself, transfer or remove a sponsor’s responsibilities. The governing documents must say whether a particular committee decision is binding, advisory, or subject to approval by another accountable party.

Membership Should Match the Strategic Remit

A steering committee needs enough perspective to recognize how a proposed platform-level direction affects science, participants, participating organizations, and practical delivery. Membership might include sponsor representatives, investigators, clinical experts, a statistician, and representatives of organizations responsible for important platform contributions. Patient or public perspectives may also be appropriate, especially when priorities or platform direction could meaningfully affect participant burden, acceptability, or relevance.

These are considerations, not a mandatory checklist. A person should have a clear reason to contribute to the committee’s remit, and the group should be small and workable enough to deliberate. A member’s presence should not be taken to imply that the member can bind the organization they represent; that authority needs to be established separately. Similarly, voting and nonvoting status should be specified rather than inferred from a job title.

Members’ interests can differ. A sponsor may be concerned with resources and continued feasibility, investigators with scientific value, and participating organizations with the demands placed on their teams. Those perspectives can improve deliberation, but they can also create competing incentives. The platform should identify relevant interests, record them, and have a consistent process for deciding when a member may participate in discussion or voting. A declaration of interest is not automatically a reason to exclude someone; the response should be proportionate to the interest and the decision.

What Strategic Oversight Covers

At platform level, steering oversight concerns the direction and coherence of the enterprise. The committee may review whether the platform’s scientific mission remains relevant, whether the planned work is consistent with that mission, and whether the overall portfolio is balanced and feasible. It can identify broad questions that warrant attention, recognize dependencies among arms, and consider whether shared resources are being used in a way consistent with platform goals.

This is different from deciding the scientific merits of every candidate intervention or applying a detailed admission or closure rule to an individual arm. Those tasks may be assigned to other bodies or handled under specified protocol procedures. Steering oversight can set broad priorities and ask for a reasoned assessment; it should not informally replace a designated review process. It also differs from coordinating day-to-day delivery. Operational management concerns implementation; steering concerns the platform’s direction and the adequacy of its overall portfolio.

Strategic oversight may includeBoundary to preserve
Reviewing whether the platform’s mission and scientific emphasis remain appropriateDo not make a decision assigned to another body or procedure merely because it is discussed at a steering meeting
Reviewing portfolio-level progress, dependencies, and broad feasibilityDo not treat aggregate portfolio review as authority to change arm-specific rules
Recommending or making platform-wide strategic decisions within delegated authorityDo not imply a recommendation is binding when approval remains with an accountable sponsor or other authority
Identifying questions, risks, or resource constraints that require follow-upDo not assume the steering committee itself carries out operational follow-up unless that is expressly assigned

Strategic discussion is only as useful as the information provided. A portfolio review should distinguish established facts from assumptions, identify missing or delayed information, and explain which decisions are actually open to the committee. Reports should be suited to the committee’s remit. For example, a summary of recruitment and delivery constraints may support a feasibility discussion, while a finding that an outcome is compelling should not be asserted without an appropriate analysis and the governance arrangements needed to review it.

Worked Examples

Worked Example: Choosing Representation for a Platform-Wide Review

A hypothetical platform is preparing a review of its scientific direction and whether its shared site network can support its planned work. The sponsor proposes a committee made up of four sponsor employees and one investigator. What should be considered before accepting that composition?

First, identify the scope: the review concerns both strategic scientific direction and feasibility across participating sites. The proposed group includes sponsor and investigator perspectives, but it has no stated representation for the site network’s delivery constraints and no explicit route for participant or public input. Those gaps matter if the discussion will weigh practical burden or participant relevance.

Second, consider whether the group can deliberate credibly. A five-person committee may be workable, but four members from one sponsor could dominate discussion, particularly if the investigator is the only other voting member. This does not prove the proposed group is unsuitable; it signals a need to examine voting arrangements, the sponsor’s role, and how differing perspectives will be heard.

A proportionate response would be to document why each member is included, consider a site-network representative and an appropriate participant-perspective mechanism, and specify who votes. The composition should match the remit rather than satisfy an arbitrary quota. No member should be assumed to represent or bind an organization without authority to do so.

Worked Example: Reviewing a Portfolio Without Taking Over an Arm Decision

A hypothetical platform has three active research areas. At a quarterly meeting, the committee sees that recruitment has reached 80% of the planned total in Area A, 45% in Area B, and 20% in Area C. The figures are descriptive; the committee has not been delegated authority to change arm-specific recruitment targets or make arm continuation decisions. What is an appropriate strategic response?

The committee can first check what the percentages mean: whether they use the same reporting date and denominator, and whether they refer to comparable recruitment plans. Assuming they are comparable, the figures indicate uneven progress, not its cause. For example, 20% in Area C might reflect a later opening date rather than a persistent feasibility problem.

The committee should therefore request or review context, such as time open, site availability, and known constraints, before drawing a portfolio-level conclusion. It might identify a need for a feasibility assessment or recommend that the designated decision-maker review Area C under the applicable process. It should not announce that Area C will close: the stated delegation does not give it that authority. The proper conclusion is that uneven recruitment warrants follow-up, not that one arm has failed or should be stopped.

Worked Example: Managing a Member’s Interest in a Resource Discussion

In a hypothetical platform, the committee is considering whether to recommend a larger share of a limited shared-site capacity for one research area. A committee member leads that area. How should the group handle the member’s participation?

The member’s leadership role is relevant because the recommendation could directly benefit the member’s area. The member should disclose the interest before the discussion, and the disclosure and the group’s response should be recorded. The committee should then follow its established conflict procedure: for example, it might allow the member to provide factual information but require the member to leave the decision discussion or abstain from voting.

The appropriate response depends on the committee’s rules and the nature of the interest; disclosure alone does not settle the question. The group should base its recommendation on stated platform-wide considerations, apply those considerations consistently across areas, and record why the decision was reached. If the member’s participation is essential to explain relevant facts, the record can distinguish that factual contribution from the member’s role in deliberation and voting.

A Practical Logic for Sound Oversight

A useful justification for the committee’s design follows from the scope of its decisions. A platform-level decision can affect several arms or participating groups. Those affected perspectives should therefore be represented or deliberately considered. Because members can have competing interests, those interests should be visible and managed. And because committee discussion does not automatically confer authority, the decision’s status and accountable decision-maker should be clear. Each step reduces a different risk: narrow perspective, unmanaged influence, or action beyond delegated authority.

1
Define the question.
State whether the matter is about platform strategy, portfolio review, operational delivery, or a decision assigned elsewhere.
2
Check the remit and evidence.
Confirm what the committee may decide or recommend, and whether the information presented is adequate for that purpose.
3
Deliberate with relevant perspectives.
Consider whose interests or expertise are relevant, and apply the agreed approach to conflicts of interest.
4
Record the outcome and route.
Document the rationale, whether the outcome is a recommendation or decision, who is responsible for follow-up, and any required approval.

Diagnostics, Alternatives, and Limitations

Several signs suggest that strategic oversight is not working as intended. The committee repeatedly discusses topics without knowing whether it has authority to decide them; the same issue receives inconsistent treatment across meetings; recommendations have no named recipient or follow-up; or members cannot tell whether a report presents comparable information across the portfolio. Another warning sign is systematic dominance by a single organization or interest group, even if the formal membership appears diverse.

When these signs occur, the remedy is not necessarily to add more meetings or members. First clarify the remit and the status of committee outputs. Then check whether the information supports the decision, whether relevant perspectives are represented, and whether conflicts have been addressed. Record unresolved questions and assign them to the party responsible for resolving them.

A committee-based model can be compared with sponsor-led consultation or separate arm-level governance. Sponsor-led consultation may be simpler, but it can provide less structured consideration of cross-platform effects. Arm-level groups can give detailed attention to their own research area, but may not see platform-wide trade-offs. A steering committee can bring those perspectives together; it also costs time and can create ambiguity if its authority overlaps with other bodies. No structure is automatically best. The arrangement should fit the platform’s agreements, complexity, and decision needs.

There are important limits. A steering committee’s review does not establish that a platform is scientifically valid, operationally feasible, or compliant with all applicable requirements. It cannot make evidence stronger by endorsing it, and it cannot transfer accountability by voting. Nor should a committee infer that an issue has been resolved just because it appears in meeting minutes. Its contribution is to make platform-level deliberation informed, representative, bounded, and traceable.

Common Mistake

A common mistake is to say, “The steering committee approved the plan, so the sponsor is no longer responsible.” This confuses a committee’s role with the sponsor’s accountability. A committee may be authorized to make specified decisions, or it may only recommend them, but its existence does not automatically remove responsibilities that remain with the sponsor. The correction is to check the applicable delegation, state whether the committee’s outcome is binding, and identify any approval or accountability that remains elsewhere.

Key takeaway: A steering committee is most useful when its membership fits its strategic remit, its portfolio review is based on appropriate information, conflicts are managed, and every decision or recommendation has a clear authority and follow-up route.

Check Your Understanding

Answer each question, then compare your reasoning with the solutions below.

  1. A committee recommends a change that affects several platform areas, but its remit says recommendations require sponsor approval. Is the change approved? Explain.
  2. A portfolio report shows lower recruitment in one area than in another. Name one conclusion the steering committee can reasonably draw and one it cannot draw from that fact alone.
  3. Why might a site-network representative be useful when the committee reviews platform feasibility?
  4. A member with a leadership role in one area participates in a discussion about allocating shared capacity. What should happen before the committee relies on the discussion’s outcome?
  5. Give one advantage and one limitation of a steering committee compared with separate arm-level governance.

Solutions. (1) No. The committee has made a recommendation; sponsor approval is still required under the stated remit. (2) It can conclude that recruitment is uneven and may warrant contextual review. It cannot conclude from the percentages alone that the area is infeasible or should close. (3) The representative may help assess whether shared sites can deliver the planned work and identify practical constraints that are not visible in a high-level scientific plan. (4) The interest should be disclosed, the committee should apply its conflict procedure, and the decision and any limits on the member’s participation should be recorded. (5) A steering committee can consider cross-platform effects in one forum; however, it can take time and may blur authority if its remit overlaps with arm-level bodies.

Clinical Biostats